Condition
Part A and B: Advanced Solid Malignancies|Part C: Malignant Mesothelioma
Estimated Enrollment: 73
Age Group: 20 Years to 130 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Masking: No masking|Primary Purpose: Other
Study ID Numbers: D4880C00010
Study First Received: May 14, 2014
Last Updated: April 12, 2017
Estimated Primary Completion Date: January 27, 2017
Primary Outcome Measures:
Adverse event
Sponsors and Collaborators:
AstraZeneca
Website Link: https://ClinicalTrials.gov/show/NCT02141347
